Latest news
Loading news…
Blueprint Medicines develops precision therapies for genomically defined cancers and rare diseases.
Blueprint Medicines was acquired by Sanofi in 2025 for $6B.
Total Funding
Available in Pro Last Funding
Available in Pro Acquisitions
1
Monthly Visits
Available in Pro Contacts
688
Company Details
Funding & Financials
Pro- Total funding
- Funding rounds
- Last funding
- Last funding type
- Last funding date
- Funding status
- Total equity funding
- Revenue range
Web Traffic
Pro- Monthly visits
- Global traffic rank
- 6-mo avg visits
- Visit duration (s)
- Pages / visit
- Bounce rate
- Rank change (mo)
Company Info
- Org types
- company
- HQ
- Cambridge, Massachusetts, United States
Acquisitions by Blueprint Medicines
Loading columns…
0 of 0Show
Page 1 / 1
Key People at Blueprint Medicines
Member of the Scientific Advisory Board
Executive Chairman
Scientific Founder
Member of the Scientific Advisory Board
Advisor
SVP of Global Regulatory Sciences
EVP of clinical development
Vice President, Translational Medicine
688
professional contacts at Blueprint Medicines
Contact execs at Blueprint Medicines →Explore 200,000+ acquisitions — free
Filter the full database across sectors, companies, dates, and deal sizes. No signup, no paywall.
Recent News related to Blueprint Medicines
Loading news…
FAQs about Blueprint Medicines
People who checked this page also checked these
Sectors Blueprint Medicines invests & acquires in
Browse the full Acquirezy directory.